Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing
The White House is scared of our country's lithium supply running out. That's why Biden issued executive order 14017 to figure out how to expand our lithium production. And this is GREAT news for one company who's gobbling up land in the lithium-rich Nevada desert.
Exec-Order 14017 Could Send This Company Skyrocket
Dennis Reilly, insider at Agile Therapeutics
Dennis Reilly Insider Alerts

Get notified the next time Dennis Reilly buys or sells Agile Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Dennis Reilly Insider Information

Reilly has had significant experience with commercial companies in the pharmaceutical and diagnostics sectors.  In 2017, he served as Chief Financial and Chief Operating Officer of Invisible Sentinel, Inc., a private company, which BioMerieux acquired in February 2019.  From 2009 to 2017, he served as Chief Financial Officer of NeoStrata Company, Inc., a privately held global leader in dermocosmetics, which was sold to Johnson & Johnson Consumer Inc. in 2016.  From 2005 to 2008, he served as the Chief Financial Officer, and prior to that as Controller, of Barrier Therapeutics, Inc., a public dermatology focused specialty pharmaceutical company, which was sold to Stiefel Laboratories, Inc. in 2008.  Mr. Reilly was the Corporate Controller at the Medicines Company from 2002 to 2005.  In addition, held positions of increasing responsibilities at Mobil Oil Corporation, which included financial statement preparation, internal audit, SEC reporting, and financial analysis.  Mr. Reilly is a C.P.A., who received his B.S. in Accounting from Villanova and his M.B.A. from Virginia Tech.

What is Dennis Reilly's net worth?

The estimated net worth of Dennis Reilly is at least $129,017.05 as of July 27th, 2021. Mr. Reilly owns 226,306 shares of Agile Therapeutics stock worth more than $129,017 as of November 30th. This net worth estimate does not reflect any other investments that Mr. Reilly may own. Learn More.

What is Dennis Reilly's salary?

As the CFO of Agile Therapeutics, Inc., Mr. Reilly earned a total compensation package of $1,106,563.00 in 2020. Mr. Reilly earned a salary of $376,833.00, stock awards of $27,751.00, options awards of $528,051.00, non-equity compensation of $153,000.00, and other compensation of $20,928.00.

How do I contact Dennis Reilly?

The corporate mailing address for Mr. Reilly and other Agile Therapeutics executives is 101 POOR FARM ROAD, PRINCETON NJ, 08540. Agile Therapeutics can also be reached via phone at (609) 683-1880 and via email at [email protected]

Has Dennis Reilly been buying or selling shares of Agile Therapeutics?

Dennis Reilly has not been actively trading shares of Agile Therapeutics during the past quarter. Most recently, on Tuesday, July 27th, Dennis Reilly bought 50,000 shares of Agile Therapeutics stock. The stock was acquired at an average cost of $1.08 per share, with a total value of $54,000.00. Following the completion of the transaction, the chief financial officer now directly owns 226,306 shares of the company's stock, valued at $244,410.48.

Who are Agile Therapeutics' active insiders?

Agile Therapeutics' insider roster includes Alfred Altomari (CEO), Jason Butch (Insider), and Dennis Reilly (CFO).

Are insiders buying or selling shares of Agile Therapeutics?

During the last year, Agile Therapeutics insiders bought shares 9 times. They purchased a total of 5,923,260 shares worth more than $5,168,160.84. The most recent insider tranaction occured on October, 13th when Major Shareholder Perceptive Advisors Llc bought 5,734,560 shares worth more than $4,874,376.00. Insiders at Agile Therapeutics own 5.6 % of the company.

Information on this page was last updated on 10/13/2021.

Dennis Reilly Insider Trading History at Agile Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/27/2021Buy50,000$1.08$54,000.00226,306View SEC Filing Icon  
5/11/2021Buy20,000$1.35$27,000.00176,306View SEC Filing Icon  
3/23/2021Buy50,000$2.05$102,500.00156,306View SEC Filing Icon  
9/28/2020Buy9,000$2.85$25,650.00106,306View SEC Filing Icon  
3/4/2020Buy50,000$2.32$116,000.0059,806View SEC Filing Icon  
See Full Table

Dennis Reilly Buying and Selling Activity at Agile Therapeutics

This chart shows Dennis Reilly's buying and selling at Agile Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Agile Therapeutics Company Overview

Agile Therapeutics logo
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patch. Its lead product candidate, Twirla, also known as AG200-15, is an investigational low-dose, non-daily prescription contraceptive. The company was founded by Chien Te Yen on December 22, 1997 and is headquartered in Princeton, NJ.
Read More

Today's Range

Now: $0.57
Low: $0.54
High: $0.58

50 Day Range

MA: $0.81
Low: $0.55
High: $1.03

2 Week Range

Now: $0.57
Low: $0.54
High: $3.77

Volume

1,383,111 shs

Average Volume

1,071,602 shs

Market Capitalization

$53.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93
Fed Decriminalization of Cannabis Could Spark New Pot Stock Boom
With Democrats now controlling both houses of Congress and the executive branch, cannabis decriminalization on the federal level could be months away. This could result in established Washington State weed companies being able to market across state lines -- setting off a bidding war for quality stocks at reasonable prices.
Get All the Details on #1 Stock